Abstract |
After a hospital-wide formulary change resulted in the replacement of filgrastim with TBO-filgrastim for all on- and off-label indications, we performed a retrospective comparison of patients with myeloma receiving 200 mg/m(2) melphalan with autologous hematopoietic stem cell transplantation to see whether the type of growth factor used post-transplant made a difference. One hundred and eighty-two consecutive patients with myeloma were studied, 91 receiving filgrastim immediately prior to the change and 91 receiving TBO-filgrastim afterward. The CD34(+) cell dose was comparable, as were other characteristics. Although the overall time to neutrophil recovery was similar for both groups, early engraftment (≤ 12 d) occurred more often (p = 0.05), and late engraftment (≥ 14 d) less often (p = 0.09) in filgrastim-treated patients. The number of documented infections was significantly less in the TBO-filgrastim group. Day 100 mortality and hospital stay were similar for the two groups. These data indicate that there is no material difference between filgrastim and TBO-filgrastim in this clinical setting.
|
Authors | Steven Trifilio, Zheng Zhou, John Galvin, Jessica L Fong, Joanne Monreal, Jayesh Mehta |
Journal | Clinical transplantation
(Clin Transplant)
Vol. 29
Issue 12
Pg. 1128-32
(Dec 2015)
ISSN: 1399-0012 [Electronic] Denmark |
PMID | 26493022
(Publication Type: Comparative Study, Journal Article)
|
Copyright | © 2015 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd. |
Chemical References |
- Hematologic Agents
- Filgrastim
|
Topics |
- Adult
- Aged
- Female
- Filgrastim
(therapeutic use)
- Follow-Up Studies
- Graft Survival
- Hematologic Agents
(therapeutic use)
- Hematopoietic Stem Cell Transplantation
(adverse effects)
- Humans
- Length of Stay
- Male
- Middle Aged
- Multiple Myeloma
(complications, therapy)
- Neutropenia
(drug therapy, etiology)
- Prognosis
- Risk Factors
- Time Factors
- Transplantation, Autologous
|